Administer Intravenous Iron, Not Intramuscular Iron
In a woman with iron-deficiency anemia who cannot tolerate oral iron, you should administer intravenous iron rather than intramuscular iron. Intramuscular iron is essentially obsolete in modern practice and carries unnecessary risks without added benefit.
Why IV Iron is the Clear Choice
The 2024 AGA guidelines explicitly state that intravenous iron should be used if the patient does not tolerate oral iron 1. Notably, intramuscular iron is not even mentioned as a treatment option in current expert consensus guidelines on iron administration 2. This omission is telling—IM iron has been effectively abandoned in contemporary practice.
Key Advantages of IV Over IM Iron:
- Modern IV formulations allow total dose infusion in 15-60 minutes, eliminating the need for multiple visits 2
- IV iron formulations that replace iron deficits with 1-2 infusions are specifically preferred over those requiring multiple administrations 1
- Superior iron store repletion: IV ferric carboxymaltose achieves dramatically better ferritin levels (412.60 µg/L) compared to oral iron (8.68 µg/L) at 3 months 3
- Better tolerability profile: While oral iron causes gastrointestinal side effects in 100% of patients, IV iron has a distinct but manageable systemic adverse event profile 3
Safety Profile: Dispelling the Myths
True anaphylaxis with IV iron is exceedingly rare, occurring in <1:200,000 administrations 2. The 2024 guidelines emphasize that all intravenous iron formulations have similar risks, and the vast majority of reactions are complement activation-related pseudo-allergy (CARPA or "Fishbane reactions"), not true anaphylaxis 1. These infusion reactions are physiologically different from anaphylactic reactions and should be treated as such 2.
In contrast, intramuscular iron administration is appropriate only in hospital settings well-equipped to treat anaphylactic crises 4, and older studies noted that systemic side effects were more common with parenteral (IM) iron 4. The requirement for specialized emergency preparedness with IM iron, combined with its lack of efficacy advantages, makes it an inferior choice.
Practical Implementation
When administering IV iron:
- Pre-infusion assessment to evaluate infusion reaction risks is essential 2
- Monitor for hypophosphatemia, particularly with ferric carboxymaltose, which can cause the "6H syndrome" (hyperphosphaturic hypophosphatemia) affecting 50-74% of patients 5
- Choose high-dose formulations that allow 1-2 infusions rather than multiple visits 1
- Have protocols ready to manage CARPA reactions (not anaphylaxis protocols) 2
Common Pitfall to Avoid
Do not prescribe IM iron based on outdated concerns about IV iron safety. The evidence shows that modern IV iron formulations are safer and more effective than historical alternatives. One retrospective study found that IM iron doses were generally too low (only 9% appropriate) and monitoring was incomplete 6, further supporting the superiority of modern IV protocols.
The clinical bottom line: IV iron is the standard of care for women with iron-deficiency anemia who cannot tolerate oral iron. IM iron has no role in contemporary practice 2, 1.